Truist on Tenet Healthcare (THC): 'We Remain Bullish on the Heels of Upbeat Management Meetings'

Truist Securities analyst David MacDonald reiterated a Buy rating and $175.00 price target on Tenet Healthcare (NYSE: THC).

The analyst commented: "We remain bullish on the heels of upbeat management meetings focused on strong core demand trends, growth/acuity opportunity across segments and attractive relative positioning given the fluid regulatory backdrop. In addition, steps taken in 2024 have meaningfully de-levered the balance sheet, free cash flow generation remains brisk, and we continue to see ongoing development and M&A opportunity at USPI alongside increased balance sheet optionality around potential share repurchase. We reiterate our Buy rating and $175 price target and continue to view the absolute/relative valuation risk/reward as attractive."

For an analyst ratings summary and ratings history on Tenet Healthcare click here. For more ratings news on Tenet Healthcare click here.

Shares of Tenet Healthcare closed at $131.75 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker